Viatris lands a court win over AstraZeneca, but generics for blockbuster inhaler still not ready to launch

Zachary Brennan

Senior Editor

It’s been 16 years since AstraZeneca’s blockbuster asthma inhaler Symbicort came to market in the US, hauling in more than $13 billion over just the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Viatris lands a court win over AstraZeneca, but generics for blockbuster inhaler still not ready to launch

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

#JPM25 live blog day 3: PhRMA chief on reforming the IRA; Gilead weighs in on China dealmaking

Vertex's bid to offer Casgevy fertility support is 'self-serving,' HHS says

Oncology biotech plots expedited approval for bone cancer drug after Phase 2 win

FDA explains why it rejected Vanda's stomach drug in late 2024

Drugmakers tout limits of IRA impact ahead of next negotiation round

BIO CEO plans to join FDA modernization advisory board under Trump administration

Vi­a­tris lands a court win over As­traZeneca, but gener­ics for block­buster in­haler still not ready to launch

Senior Editor

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Viatris lands a court win over AstraZeneca, but generics for blockbuster inhaler still not ready to launch